NDAORALCAPSULE
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
8/8 — Comprehensive
CAMZYOS (mavacamten) by Bristol Myers Squibb is cardiac myosin inhibitors [moa]. Approved for obstructive hypertrophic cardiomyopathy, hypertrophic cardiomyopathy. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAMZYOS (mavacamten) is an oral cardiac myosin inhibitor approved by the FDA on April 28, 2022, developed by Bristol Myers Squibb. It is indicated for symptomatic treatment of obstructive hypertrophic cardiomyopathy (HCM), representing the first and only first-in-class mechanism targeting the underlying cardiac pathophysiology. The drug works by directly inhibiting cardiac myosin, reducing the force of heart muscle contraction and alleviating obstruction. CAMZYOS fills a significant unmet need in a rare but serious cardiac condition with limited prior pharmacologic options.
$0.1BPart D
10.0 years to LOEMechanism of Action
Cardiac Myosin Inhibitors
Pharmacologic Class:
Cardiac Myosin Inhibitor
Worked on CAMZYOS at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.